FDA delays decision on Exubera
In September, an FDA advisory committee recommended approval of Exubera for the treatment of adults with type 1 and type 2 diabetes. The FDA is not obligated to
The US Food and Drug Administration (FDA) has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).